- Your cart is empty
- Continue Shopping
Triple Receptor Agonist Metabolic Peptide (RT)
$300.00
RT is a next-generation triple-agonist research peptide designed to activate GLP-1, GIP, and glucagon receptors simultaneously. This unique multi-pathway mechanism makes RT of significant interest in metabolic, weight-regulation and energy balance research models. Compared to singe or dual agonist incretin peptides, RT is studied for its potential to influence appetite signaling, insulin dynamics, and energy expenditure through coordinated receptor activity. This product is supplied as a 10mg lyophilized peptide intended strictly for laboratory research only. This peptide works on the incretin system, a gut derived hormonal signaling network that links food intake to insulin release, glucose control, appetite regulation and energy balance
23 in stock
Add to cart
Buy Now
Key highlights:
- Triple-agonist peptide: GLP-1 + GIP + Glucagon
- Advanced metabolic research compound
- Lyophilized powder for reconstitution
- High purity research material
- Suitable for controlled laboratory and investigatory studies
- Not FDA-Approved, not for human or veterinary use
General Benefits:
- Supports multi-receptor metabolic signaling pathways
- Allows investigation of appetite regulation mechanisms
- Enables study of energy expenditure and fat oxidation signaling
- Useful for examining insulin sensitivity pathways in research models
- Offers broader metabolic insight compared to GLP-1 only peptides
Research Benefits:
-
Studied for enhanced weight loss signaling compared tosingle-agonist incretins
- Enables exploration of metabolic flexibility and energy balance
- Valuable in research on insulin resistance and glucose regulation
- Useful for investigating lean mass preservation vs fat mass reduction
-
Supports advanced research into hormonal synergy within the incretinsystem (A gut derived hormonal signaling network that links foodintake to insulin release, glucose control, appetite regulation andenergy balance).
Reviews
There are no reviews yet.